Pandorum's artificial liver tissues not only represent a major step towards the on-demand manufacturing of human organs for transplant, but also has potential to be a game changer for developing new medicines and vaccines, the company said in a statement.
"Liver toxicity and drug metabolism are the key hurdles, and contributors to failed human trials. Our 3D bio-printed mini-livers that mimic the human liver will serve as test platforms for discovery and development of drugs with better efficacy, less side-effects and at lower costs," Pandorum Technologies MD and co-founder Arun Chandru said.
"This is a significant milestone," Dr Tuhin Bhowmick, who holds a PhD from Indian Institute of Science and Pandorum Technologies co-founder said.
"Being able to engineer complex tissues such as the human liver is no easy task," he added.
"Development of artificial organs has numerous clinical uses. Cell based organoids can be used to develop bio-artificial liver support systems for preserving life in patients who have developed liver failure.
"In the near future, such bio-printed organs will address the acute shortage of human organs available for surgical transplantation," Bhowmick said.
and 10 years on R&D to get a single new drug to market with the approval of the Food and Drug Administration (FDA). The global market for in vitro toxicity testing alone is expected to reach USD 4 billion by 2018.
"It is a multi-billion dollar fast growing market, and we intend to continue being a leader. More importantly, our technology has the potential to impact millions of lives," Chandru said.
Pandorum Technologies, founded in 2011 by an academic entrepreneurs, is a biotechnology startup with distinct synergy of life science and engineering competencies.
Pandorum is supported by grants from the Biotechnology Industry Research Assistance Council (BIRAC), Government of India, and is located in the Centre for Cellular and Molecular Platforms (C-CAMP), Bengaluru Bio-Cluster.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
